What was the per-share value used in the NPCE tax withholding transaction?

The transaction used a value of $14.13 per share for the 358 shares of NeuroPace common stock withheld on August 27, 2026 to satisfy Morrell’s tax withholding obligations related to a restricted stock unit vesting.

NeuroPace (NASDAQ: NPCE) CMO has 358 shares withheld for taxes

Q: What insider transaction did NPCE report for Martha Morrell on August 27, 2026?

NeuroPace reported that Chief Medical Officer Martha Morrell had 358 shares of common stock withheld on August 27, 2026 to satisfy tax withholding obligations arising from the vesting of a restricted stock unit award, at a reference price of $14.13 per share.

Q: Was the NPCE Form 4 transaction a market sale or a tax withholding event?

The Form 4 describes a tax withholding event, not an open-market sale. 358 shares were withheld by NeuroPace to pay tax withholding obligations tied to vesting of a restricted stock unit award for Chief Medical Officer Martha Morrell.

Q: Does the NPCE Form 4 indicate trading under a Rule 10b5-1 plan?

No. The filing’s 10b5-1 checkbox is not affirmed (set to false), and the footnote states only that shares were withheld to satisfy tax withholding obligations on a restricted stock unit vesting.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

NeuroPace Inc (NPCE) reported an insider equity withholding transaction by Chief Medical Officer Martha Morrell. On August 27, 2026, 358 shares of common stock were withheld by the company at $14.13 per share to cover tax withholding obligations related to the vesting of a restricted stock unit award. After this withholding, Morrell directly held 51,692 shares of NeuroPace common stock.

Insider Trade Summary

Net Seller: 358 shares

Net Sell 1 txn

Insider Morrell Martha

Role CHIEF MEDICAL OFFICER

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock ^F1	358	$14.13	$5K

Holdings After Transaction: Common Stock — 51,692 shares (Direct)

Footnotes (1)

F1. Represents the number of shares withheld by the Issuer on August 27, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award.

Key Figures

Shares withheld: 358 shares of Common Stock Per-share value: $14.13 per share Shares held after transaction: 51,692 shares of Common Stock

3 metrics

Shares withheld 358 shares of Common Stock Withheld on August 27, 2026 to satisfy tax withholding obligations

Per-share value $14.13 per share Value used for the 358 shares withheld on August 27, 2026

Shares held after transaction 51,692 shares of Common Stock Direct holdings of Martha Morrell following the August 27, 2026 transaction

Key Terms

restricted stock unit award, tax withholding obligations, withheld by the Issuer

3 terms

restricted stock unit award financial

"in connection with the vesting of a restricted stock unit award"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

tax withholding obligations financial

"to satisfy tax withholding obligations in connection with the vesting"

withheld by the Issuer financial

"Represents the number of shares withheld by the Issuer on August 27, 2026"

FAQ

What insider transaction did NPCE report for Martha Morrell on August 27, 2026?

NeuroPace reported that Chief Medical Officer Martha Morrell had 358 shares of common stock withheld on August 27, 2026 to satisfy tax withholding obligations arising from the vesting of a restricted stock unit award, at a reference price of $14.13 per share.

Was the NPCE Form 4 transaction a market sale or a tax withholding event?

The Form 4 describes a tax withholding event, not an open-market sale. 358 shares were withheld by NeuroPace to pay tax withholding obligations tied to vesting of a restricted stock unit award for Chief Medical Officer Martha Morrell.

How many NPCE shares does Martha Morrell hold after the reported transaction?

After the August 27, 2026 tax-withholding transaction, Chief Medical Officer Martha Morrell directly holds 51,692 shares of NeuroPace common stock, as reported in the Form 4 filing.

Does the NPCE Form 4 indicate trading under a Rule 10b5-1 plan?

No. The filing’s 10b5-1 checkbox is not affirmed (set to false), and the footnote states only that shares were withheld to satisfy tax withholding obligations on a restricted stock unit vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/28/2026 - 05:04 PM Accepted by SEC EDGAR 08/28/2026 - 05:03 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morrell Martha

(Last)

(First)

(Middle)

C/O NEUROPACE INC.

455 N. BERNARDO AVENUE

(Street)

MOUNTAIN VIEW

CALIFORNIA

94043

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/27/2026		F		358⁽¹⁾	D	$14.13⁽¹⁾	51,692	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the number of shares withheld by the Issuer on August 27, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award.

Remarks:

	/s/ Leah Akin, Attorney-in-Fact	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR